Statistik Asas
| LEI | 549300YSK3QDSFR5EU59 |
| CIK | 1093557 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DexCom, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 30, 2025 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan SAN DIEGO - (BUSINESS WIRE-July 30, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: •Revenue grew 15% year-over-year to $1.157 billion on a reported basi |
|
| July 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEX |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 25, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 29, 2025 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 to Form SD DexCom, Inc. Conflict Minerals Report For the Reporting Period from January 1, 2024 to December 31, 2024 This Conflict Minerals Report (“CMR”) has been prepared by DexCom, Inc. (herein referred to, alternatively, as “Dexcom,” “we,” “our” and “us”) for the reporting period from January 1, 2024 to December 31, 2024. This CMR is presented to comply with Rule 13p-1 (“Rule 13p-1 |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DEXCOM, INC. (Exact name of the registrant as specified in its charter) Delaware 000-51222 33-0857544 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive, San Diego, CA 92121 (Address of principal |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 13, 2025 |
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO Exhibit 99.1 Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO SAN DIEGO-(BUSINESS WIRE)—May 13, 2025- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer which he has held since 2022. With more than 21 years of |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 9, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) DexCom, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per |
|
| May 9, 2025 |
Amended and Restated 2015 Equity Incentive Plan. Exhibit 10.1 DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN (Adopted by the Board on March 7, 2025) 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an opp |
|
| May 9, 2025 |
As filed with the Securities and Exchange Commission on May 9, 2025 As filed with the Securities and Exchange Commission on May 9, 2025 Registration No. |
|
| May 9, 2025 |
Amended and Restated 2015 Employee Stock Purchase Plan. Exhibit 10.2 DEXCOM, INC. AMENDED AND RESTATED 2015 EMPLOYEE STOCK PURCHASE PLAN (Adopted by the Board on March 7, 2025) 1.PURPOSE. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company through payroll deductions, to enhance such employees’ sense of participation in the affairs of the |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 1, 2025 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program SAN DIEGO - (BUSINESS WIRE-May 1, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: •Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-ove |
|
| May 1, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 1, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DE |
|
| March 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 21, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 25, 2025 |
Letter from Ernst & Young LLP dated March 21, 2025 Exhibit 16.1 March 21, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated March 21, 2025, of DexCom, Inc. and are in agreement with the statements contained in the first paragraph insofar as related to the date of notification of our dismissal as the Company’s independent registered public accounting firm and in t |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 10, 2025 |
Dexcom Appoints Renée Galá to Board of Directors Exhibit 99.1 Dexcom Appoints Renée Galá to Board of Directors SAN DIEGO - (BUSINESS WIRE-March 10, 2025) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the l |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 18, 2025 |
Exhibit 10.15 SEVERANCE AGREEMENT AND GENERAL RELEASE RECITALS This Severance Agreement and General Release (“Agreement”) is made by and between Teri Lawver (“Executive”) and Dexcom, Inc., its subsidiaries, affiliates, successors, and assigns (“Company” or “Employer”) (collectively, the “Parties”): WHEREAS, Executive is currently employed by Company as Executive Vice President, Chief Commercial Of |
|
| February 18, 2025 |
As filed with the Securities and Exchange Commission on February 14, 2025 As filed with the Securities and Exchange Commission on February 14, 2025 Registration No. |
|
| February 18, 2025 |
Confidential Settlement and Patent License Agreement Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. CONFIDENTIAL SETTLEMENT AND PATENT LICENSE AGREEMENT This CONFIDENTIAL SETTLEMENT AND PATENT LICENSE AGREEMENT (the “Agreement”) is made and entered as of December 20, 2024 (the “Effective Dat |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51222 DEXCOM, INC. (Exact name o |
|
| February 18, 2025 |
Description of Securities Registered Under Section 12 of the Exchange Act. Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, DexCom, Inc. (the “Company,” “we” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. Description of Capital Stock The following summary of the terms of our capital stock is b |
|
| February 18, 2025 |
Amended and Restated 2015 Equity Incentive Plan and forms of award agreements. Exhibit 10.17 DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN1 (Adopted by the Board on April 18, 2019) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an |
|
| February 18, 2025 |
Exhibit 21.1 DEXCOM, INC. SUBSIDIARY (Name under which subsidiary does business) JURISDICTION OF INCORPORATION DEXCOM INTERNATIONAL LIMITED CYPRUS ROADRUNNER GREEN LIMITED IRELAND DEXCOM (MALAYSIA) SDN. BHD. MALAYSIA |
|
| February 18, 2025 |
Exhibit 4.4 DEXCOM, INC. And , as Trustee INDENTURE Dated as of TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXECUTION AND AUT |
|
| February 18, 2025 |
Exhibit 19.1 DEXCOM, INC. Insider Trading Policy As Adopted by the Board of Directors on March 11, 2005 and amended through January 1, 2025 I.PURPOSE It is illegal for any employee, officer or director of DexCom, Inc. (collectively, with its subsidiaries, the “Company”) to trade in the securities of the Company while in the possession of material nonpublic information about the Company. A “trade” |
|
| February 18, 2025 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] DEXCOM, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY IS % |
|
| February 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) DexCom, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| February 13, 2025 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results SAN DIEGO - (BUSINESS WIRE-February 13, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: •Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on a |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 13, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 13, 2025 |
Exhibit 99.1 Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook SAN DIEGO, CA - (BUSINESS WIRE-January 13, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U. |
|
| January 13, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 24, 2024 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly report on Form 10-Q for the quarter ended September 30, 2024 of the Company (the “Report”) fully complies with the requirements of Secti |
|
| October 24, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 24, 2024 |
Exhibit 3.1 AMENDED & RESTATED BYLAWS OF DEXCOM, INC. (a Delaware corporation) As amended October 22, 2024 TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 4 Section 1.1. Annual Meetings 4 Section 1.2. Special Meetings 4 Section 1.3. Notice of Meetings 4 Section 1.4. Adjournments 4 Section 1.5. Quorum 4 Section 1.6. Organization 5 Section 1.7. Voting 5 Section 1.8. Proxies 5 Section 1.9. Fixing Date |
|
| October 24, 2024 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly report on Form 10-Q for the quarter ended September 30, 2024 of the Company (the “Report”) fully complies with the req |
|
| October 24, 2024 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| October 24, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5122 |
|
| October 24, 2024 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| October 24, 2024 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports Third Quarter 2024 Financial Results SAN DIEGO - (BUSINESS WIRE-October 24, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: •Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. •U.S. revenue de |
|
| July 25, 2024 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly report on Form 10-Q for the quarter ended June 30, 2024 of the Company (the “Report”) fully complies with the requirem |
|
| July 25, 2024 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly report on Form 10-Q for the quarter ended June 30, 2024 of the Company (the “Report”) fully complies with the requirements of Section 13 |
|
| July 25, 2024 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program SAN DIEGO - (BUSINESS WIRE-July 25, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: •Revenue grew 15% year-over-year to $1.004 billion on a reported |
|
| July 25, 2024 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| July 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEX |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 25, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 25, 2024 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DEXCOM, INC. (Exact name of the registrant as specified in its charter) Delaware 000-51222 (State or other jurisdiction of incorporation) (Commission file number) 6340 Sequence Drive, San Diego, CA 92121 (Address of principal executive offices) (Zip code) Michael J. Brown EVP, Chief Legal |
|
| May 29, 2024 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form Exhibit 1.01 to Form SD DexCom, Inc. Conflict Minerals Report For the Reporting Period from January 1, 2023 to December 31, 2023 This Conflict Minerals Report (“CMR”) has been prepared by DexCom, Inc. (herein referred to, alternatively, as “Dexcom,” “we,” “our” and “us”) for the reporting period from January 1, 2023 to December 31, 2023. This CMR is presented to comply with Rule 13p-1 (“Rule 13p-1 |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 25, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 25, 2024 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| April 25, 2024 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the quarter ended March 31, 2024 of the Company (the “Report”) fully complies with the requirements of Section 1 |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DE |
|
| April 25, 2024 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| April 25, 2024 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports First Quarter 2024 Financial Results SAN DIEGO - (BUSINESS WIRE-April 25, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: •Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. •U.S. revenue and in |
|
| April 25, 2024 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the quarter ended March 31, 2024 of the Company (the “Report”) fully complies with the require |
|
| April 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. WARRANT TERMINATION AGREEMENT dated as of February 13, 2024 DexCom, Inc. and Bank of America, N.A. THIS WARRANT TERMINATION AGREEMENT (this “Agreement”) with respect to the Warrants Confirmatio |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 13, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 13, 2024 |
DXCM / DexCom, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0751-dexcominc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Dexcom Inc Title of Class of Securities: Common Stock CUSIP Number: 252131107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| February 8, 2024 |
2015 Employee Stock Purchase Plan and forms of subscription agreements. Exhibit 10.12 DEXCOM, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN1 Effective On May 28, 2015, As Amended On December 13, 2019 1.PURPOSE. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company through payroll deductions, to enhance such employees’ sense of participation in the affairs of the |
|
| February 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 8, 2024 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results SAN DIEGO - (BUSINESS WIRE-February 8, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: •Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis |
|
| February 8, 2024 |
Description of Securities Registered Under Section 12 of the Exchange Act. Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, DexCom, Inc. (the “Company,” “we” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. Description of Capital Stock The following summary of the terms of our capital stock is b |
|
| February 8, 2024 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this annual report on Form 10-K of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| February 8, 2024 |
Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is executed on November 20, 2018 (the “Effective Date”) |
|
| February 8, 2024 |
Securities Trades by Company Personnel Exhibit 19.1 DEXCOM, INC. Procedures and Guidelines Governing Securities Trades by Company Personnel As Adopted by the Board of Directors on March 11, 2005 and amended through February 27, 2023 I. PURPOSE It is illegal for any employee, officer or director of DexCom, Inc. (collectively, with its subsidiaries, the “Company”) to trade in the securities of the Company while in the possession of mater |
|
| February 8, 2024 |
Consent of Independent Registered Public Accounting Firm. Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: ◦Registration Statement (Form S-3 Nos. 333-206619, 333-211101, and 333-261265) of DexCom, Inc., ◦Registration Statement (Form S-8 No. 333-204699) pertaining to the 2015 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan of DexCom |
|
| February 8, 2024 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the annual Report on Form 10-K for the year ended December 31, 2023 of the Company (the “Report”) fully complies with the requirements of Section 13(a |
|
| February 8, 2024 |
Amended and Restated 2015 Equity Incentive Plan and forms of award agreements. Exhibit 10.13 DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN1 (Adopted by the Board on April 18, 2019) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an |
|
| February 8, 2024 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this annual report on Form 10-K of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 8, 2024 |
Exhibit 21.01 DEXCOM, INC. SUBSIDIARY (Name under which subsidiary does business) JURISDICTION OF INCORPORATION SweetSpot Diabetes Care, Inc. Delaware TypeZero Technologies, Inc. Delaware DexCapital, LLC Delaware The Glucose Program, LLC Delaware Nintamed Handels GmbH Austria DexCom Canada, Co. Canada DexCom International Ltd. Cyprus DexCom Deutschland GmbH Germany DexCom Lithuania UAB Lithuania D |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51222 DEXCOM, INC. (Exact name o |
|
| February 8, 2024 |
Exhibit 97.1 DexCom, Inc. Compensation Recovery Policy (Adopted August 21, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement due to the Company’s material noncomplia |
|
| February 8, 2024 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the annual Report on Form 10-K for the year ended December 31, 2023 of the Company (the “Report”) fully complies with the requiremen |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 8, 2024 |
Exhibit 99.1 Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook The company also announced Stelo, its new glucose sensor for people with type 2 diabetes who do not use insulin, has been submitted to the U.S. Food and Drug Administration for review and is expected to launch in the U.S. in summer 2024 SAN DIEGO, CA - (BUSINESS WIRE-Janu |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 26, 2023 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended September 30, 2023 of the Company (the “Report”) fully complies with the requirements of Sectio |
|
| October 26, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 26, 2023 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program SAN DIEGO - (BUSINESS WIRE-October 26, 2023) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: •Revenue grew 27% versus the same qu |
|
| October 26, 2023 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended September 30, 2023 of the Company (the “Report”) fully complies with the requ |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 26, 2023 |
Exhibit 10.02 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER THIRTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER THIRTEEN TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“Amendment”) is made e |
|
| October 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5122 |
|
| October 26, 2023 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| October 26, 2023 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| October 26, 2023 |
Exhibit 10.01 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER SIXTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER SIXTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“Am |
|
| August 28, 2023 |
Dexcom Appoints Rimma Driscoll to Board of Directors EXHIBIT 99.01 Dexcom Appoints Rimma Driscoll to Board of Directors SAN DIEGO-(BUSINESS WIRE)—August 28, 2023 - DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023. Ms. Driscoll is an accomplished leader with significant experience developing, guiding and exe |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 24, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 27, 2023 |
to Amended and Restated Non-Exclusive Distribution Agreement, dated June 1 Exhibit 10.07 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER FIFTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER FIFTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“Am |
|
| July 27, 2023 |
Exhibit 10.03 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER FOURTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER FOURTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“ |
|
| July 27, 2023 |
EXHIBIT 10.06 FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of June 1, 2023, is entered into by and among DEXCOM, INC., a Delaware corporation (the “Borrower”), the Lenders described below party hereto, and JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, a national banking association (in |
|
| July 27, 2023 |
Non-Exclusive Distribution Agreement, dated Exhibit 10.04 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER TWELVE TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER TWELVE TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“Amendment”) is made effective as of May 15, 20 |
|
| July 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEX |
|
| July 27, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 27, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 27, 2023 |
Non-Exclusive Distribution Agreement, dated Exhibit 10.05 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER THIRTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER THIRTEEN TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“ |
|
| July 27, 2023 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended June 30, 2023 of the Company (the “Report”) fully complies with the requirements of Section 13( |
|
| July 27, 2023 |
Non-Exclusive Distribution Agreement, dated Exhibit 10.02 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER ELEVEN TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER ELEVEN TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“Amendment”) is made effective as of March 15, |
|
| July 27, 2023 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| July 27, 2023 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| July 27, 2023 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended June 30, 2023 of the Company (the “Report”) fully complies with the requireme |
|
| July 27, 2023 |
DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports Second Quarter 2023 Financial Results SAN DIEGO - (BUSINESS WIRE-July 27, 2023) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights: •Revenue grew 25% versus the same quarter of the prior year to $871.3 million on a reported basis and 26% on an organic1 basis. •U.S. re |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 26, 2023 |
ABOUT NON-GAAP FINANCIAL MEASURES Exhibit 99.1 Dexcom Updates Long-Range Financial Targets SAN DIEGO, CA - (BUSINESS WIRE-June 23, 2023) - DexCom, Inc. (NASDAQ:DXCM) today announced an update to its long-range financial targets at its 2023 Investor Day. Based on the company’s strong performance in the first two years of the target period, Dexcom is updating its year-end 2025 financial targets to the following levels: •2025 Revenue |
|
| May 31, 2023 |
DexCom, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2022. Exhibit 1.01 to Form SD DexCom, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2022 This Conflict Minerals Report (“CMR”) has been prepared by DexCom, Inc. (herein referred to, alternatively, as “Dexcom,” “we,” “our” and “us”). This CMR for the reporting period January 1 to December 31, 2022 is presented to comply with the final conflict minerals implementing rule |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DEXCOM, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51222 33-0857544 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 6340 Sequence Drive, San Diego, CA 92121 (Address of Principal Executi |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Numb |
|
| May 19, 2023 |
DexCom, Inc. Amended and Restated Severance and Change in Control Plan. EX-10.1 Exhibit 10.1 AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL PLAN This Amended and Restated Severance and Change in Control Plan (this “Plan”) was adopted by the Board of Directors (the “Board”) of DexCom, Inc., a Delaware corporation (the “Company”) on May 18, 2023 (the “Effective Date”). Each executive that is provided benefits under this Plan (“Executive”) shall be eligible to rece |
|
| May 5, 2023 |
[Signature Page to [Base][Additional] Capped Call Confirmation] EX-99.1 Exhibit 99.1 [Dealer name and address] May [], 2023 To: DexCom, Inc. 6340 Sequence Drive San Diego, CA 92121 Attention: Leslie Ludtke, Treasurer Telephone No.: Email address: Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [] (“Dealer”) and De |
|
| May 5, 2023 |
EX-4.1 Exhibit 4.1 DEXCOM, INC. 0.375% CONVERTIBLE SENIOR NOTES DUE 2028 INDENTURE DATED AS OF MAY 5, 2023 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 10 Section 1.03. Rules of Construction 11 Section 1.04. References to Additional Interest 11 ARTICL |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Numbe |
|
| May 3, 2023 |
DEXCOM PRICES UPSIZED OFFERING OF $1.1 BILLION OF 0.375% CONVERTIBLE SENIOR NOTES DUE 2028 EX-99.1 Exhibit 99.1 DEXCOM PRICES UPSIZED OFFERING OF $1.1 BILLION OF 0.375% CONVERTIBLE SENIOR NOTES DUE 2028 SAN DIEGO, CA. - (BUSINESS WIRE - May 3, 2023) - DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed t |
|
| May 3, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Numbe |
|
| May 2, 2023 |
DEXCOM ANNOUNCES PROPOSED OFFERING OF $1.0 BILLION OF CONVERTIBLE SENIOR NOTES Exhibit 99.1 DEXCOM ANNOUNCES PROPOSED OFFERING OF $1.0 BILLION OF CONVERTIBLE SENIOR NOTES SAN DIEGO, CA.—(BUSINESS WIRE—May 2, 2023)—DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably |
|
| May 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Numbe |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DE |
|
| April 27, 2023 |
Exhibit 10.02 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER TEN TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER TEN TO THE NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“Amendment”) is made effective as of February 1, 2023 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 27, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 27, 2023 |
EXHIBIT 10.01 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER NINE TO THE NON-EXCLUSIVE WHOLESALE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER NINE TO THE NON-EXCLUSIVE WHOLESALE DISTRIBUTION AGREEMENT (“Amendment”) is made effective |
|
| April 27, 2023 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended March 31, 2023 of the Company (the “Report”) fully complies with the requirem |
|
| April 27, 2023 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| April 27, 2023 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| April 27, 2023 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended March 31, 2023 of the Company (the “Report”) fully complies with the requirements of Section 13 |
|
| April 27, 2023 |
DexCom, Inc., Table A Consolidated Balance Sheets (In millions, except par value data) Exhibit 99.1 Dexcom Reports First Quarter 2023 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-April 27, 2023) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights: •Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic1 basis. •U.S |
|
| April 27, 2023 |
Exhibit 10.03 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NUMBER TWELVE TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT This AMENDMENT NUMBER TWELVE TO THE AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT (“Amen |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2023 |
Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL DISTRIBUTION SERVICES AGREEMENT This Distribution Services Agreement (“Agreement”) is made as of the 7th day of November, 2015, by and between AmerisourceBergen Drug Corporation, with an addres |
|
| February 9, 2023 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this annual report on Form 10-K of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 9, 2023 |
Consent of Independent Registered Public Accounting Firm. Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: ◦Registration Statement (Form S-3 Nos. 333-206619, 333-211101, 333-228495, and 333-261265) of DexCom, Inc., ◦Registration Statement (Form S-8 No. 333-204699) pertaining to the 2015 Equity Incentive Plan and the 2015 Employee Stock Purchase Pl |
|
| February 9, 2023 |
2015 Employee Stock Purchase Plan, amended on December 13, 2019 and form of subscription agreement.* Exhibit 10.19 DEXCOM, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN Effective On May 28, 2015, As Amended On December 13, 2019 1.PURPOSE. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company through payroll deductions, to enhance such employees’ sense of participation in the affairs of the C |
|
| February 9, 2023 |
Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT between DEXCOM, INC. and BYRAM HEALTHCARE Dated February 1, 2016 AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT THIS AMENDE |
|
| February 9, 2023 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the annual Report on Form 10-K for the period ended December 31, 2022 of the Company (the “Report”) fully complies with the requirem |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 9, 2023 |
Exhibit 10.09 OFFICE LEASE KILROY REALTY 6340 SEQUENCE DRIVE KILROY REALTY, L.P. a Delaware limited partnership, as Landlord, and DEXCOM, INC., a Delaware corporation, as Tenant. TABLE OF CONTENTS Page ARTICLE 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 3 ARTICLE 2 LEASE TERM; OPTION TERM(S) 4 ARTICLE 3 BASE RENT 7 ARTICLE 4 ADDITIONAL RENT 8 ARTICLE 5 USE OF PREMISES 13 ARTICLE 6 SERVICES AND |
|
| February 9, 2023 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this annual report on Form 10-K of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| February 9, 2023 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the annual Report on Form 10-K for the period ended December 31, 2022 of the Company (the “Report”) fully complies with the requirements of Section 13 |
|
| February 9, 2023 |
Exhibit 21.01 DEXCOM, INC. SUBSIDIARY (Name under which subsidiary does business) JURISDICTION OF INCORPORATION SweetSpot Diabetes Care, Inc. Delaware TypeZero Technologies, Inc. Delaware DexCapital, LLC Delaware The Glucose Program, LLC Delaware Nintamed Handels GmbH Austria DexCom Canada, Co. Canada DexCom Deutschland GmbH Germany DexCom Lithuania UAB Lithuania DexCom (Malayisa) Sdn Bhd. Malaysi |
|
| February 9, 2023 |
EX-10.18 11 dxcm12312022ex1018-fourtha.htm EX-10.18 Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. FOURTH AMENDMENT TO OFFICE LEASE This FOURTH AMENDMENT TO OFFICE LEASE (“Fourth Amendment”) is made and entered into as of the 9th day of Se |
|
| February 9, 2023 |
Amended and Restated 2015 Equity Incentive Plan and forms of award agreements.* Exhibit 10.17 DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN (Adopted by the Board on April 18, 2019) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an |
|
| February 9, 2023 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [******], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Amendment Number One to Non-Exclusive Distribution Agreement This Amendment Number One to the Non-Exclusive Distribution Agreement (“Amendment Number One”) is made as of March 29, 2011, by |
|
| February 9, 2023 |
DXCM / DexCom, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0728-dexcominc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Dexcom Inc. Title of Class of Securities: Common Stock CUSIP Number: 252131107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pur |
|
| February 9, 2023 |
Severance and Change in Control Plan and form of participation agreement.* Exhibit 10.16 Severance and Change in Control Plan This Severance and Change in Control Plan (this “Plan”) was adopted by the Board of Directors of DexCom, Inc., a Delaware corporation (the “Company”) on June 1, 2017 (the “Effective Date”). Each executive that is provided benefits under this Plan (“Executive”) shall be eligible to receive payments from the Plan only if he or she has signed the Par |
|
| February 9, 2023 |
Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Execution Version - CONFIDENTIAL AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT between DEXCOM, INC. and VERILY LIFE SCIENCES LLC (FORMERLY GOOGLE LIFE SCIENCES LLC) THIS AMENDMENT NO. |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51222 DEXCOM, INC. (Exact name of r |
|
| February 9, 2023 |
Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AGREEMENT between DEXCOM, INC. and DIABETES MANAGEMENT AND SUPPLIES, LLC Dated August 10, 2015 AMENED AND RESTATED NON-EXCLUSIVE DISTRIBUTION AG |
|
| February 9, 2023 |
Exhibit 10.14 AIA® Document A102™- 2007 Standard Form of Agreement Between Owner and Contractor where the basis of payment is the Cost of the Work Plus a Fee with a Guaranteed Maximum Price AGREEMENT made as of the 2nd day of May in the year 2016 (In words, indicate day, month and year.) BETWEEN the Owner: (Name, legal status, address and other information) DexCom, Inc. 6340 Sequence Drive San Die |
|
| February 9, 2023 |
Exhibit 10.20 LEASE 10455 Pacific Center Court San Diego, California Basic Lease Information Date: January 31, 2020 Landlord: GC Pacific Center Court Owner LLC, a Delaware limited liability company Tenant: Dexcom, Inc., a Delaware corporation Building (section 1.1): That certain building located at 10455 Pacific Center Court, San Diego, California 92121 Premises (section 1.1): A portion of the Bui |
|
| February 9, 2023 |
Exhibit 99.1 Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-February 9, 2023) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights: •Revenue grew 17% versus the same quarter of the prior year to $815.2 million on a reported b |
|
| January 9, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| January 9, 2023 |
EX-99.1 2 a991jpmorgan192023.htm EX-99.1 Exhibit 99.1 Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook SAN DIEGO, CA - (BUSINESS WIRE-January 9, 2023) - DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ende |
|
| October 27, 2022 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| October 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5122 |
|
| October 27, 2022 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended September 30, 2022 of the Company (the “Report”) fully complies with the requ |
|
| October 27, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| October 27, 2022 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| October 27, 2022 |
Exhibit 99.1 Dexcom Reports Third Quarter 2022 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-October 27, 2022) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights: ?Revenue grew 18% versus the same quarter of the prior year to $769.6 million on a reported basis and 20% on an organic1 basis |
|
| October 27, 2022 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended September 30, 2022 of the Company (the “Report”) fully complies with the requirements of Sectio |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 25, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| July 28, 2022 |
Exhibit 10.02 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Redistribution Center (RDC) Agreement THIS REDISTRIBUTION CENTER (RDC) AGREEMENT (?Agreement?), is made effective as of June 6, 2022 (the ?Effective Date?), by and between DexCom, Inc. ( |
|
| July 28, 2022 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| July 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEX |
|
| July 28, 2022 |
Exhibit 99.1 Dexcom Reports Second Quarter 2022 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-July 28, 2022) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022. Second Quarter 2022 Financial Highlights: ?Revenue grew 17% versus the same quarter of the prior year to $696.2 million on a reported basis and 16% on an organic1 basis. ?U.S |
|
| July 28, 2022 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended June 30, 2022 of the Company (the ?Report?) fully complies with the requireme |
|
| July 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 28, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| July 28, 2022 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended June 30, 2022 of the Company (the ?Report?) fully complies with the requirements of Section 13( |
|
| July 28, 2022 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 26, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| July 28, 2022 |
Exhibit 10.01 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. CARDINAL HEALTH National Logistics Center / Brokerage Logistics Center AGREEMENT ?Company?: Dexcom, Inc. Company and Cardinal Health*, intending to be legally bound, agree as follows: 1. |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Numb |
|
| June 10, 2022 |
Restated Certificate of Incorporation of DexCom, Inc. Exhibit 3.1 DEXCOM, INC. RESTATED CERTIFICATE OF INCORPORATION DexCom, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the corporation is DexCom, Inc. The date of filing its original Certificate of Incorporation with the Secretary of State was May 13, 1999. This Restated Certificate of Incorporation of |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Num |
|
| May 31, 2022 |
SD 1 a2022formsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DEXCOM, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51222 33-0857544 (State or other jurisdiction of incorporation or organization ) (Commission File Number) (IRS Employer Identification No.) 6340 Sequence Drive, San Diego, California 92 |
|
| May 31, 2022 |
DexCom, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2021. Exhibit 1.01 to Form SD DexCom, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2021 This Conflict Minerals Report (?CMR?) has been prepared by DexCom, Inc. (herein referred to, alternatively, as ?Dexcom,? ?we,? ?our? and ?us?). This CMR for the reporting period January 1 to December 31, 2021 is presented to comply with the final conflict minerals implementing rule |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Numb |
|
| May 5, 2022 |
United States securities and exchange commission logo May 5, 2022 Kevin R. Sayer President and Chief Executive Officer DEXCOM, INC. 6340 Sequence Drive San Diego, California 92121 Re: DEXCOM, INC. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed on February 14, 2022 File No. 000-51222 Dear Mr. Sayer: We have completed our review of your filings. We remind you that the company and its ma |
|
| May 3, 2022 |
CORRESP 1 filename1.htm May 3, 2022 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Christie Wong Kristin Lochhead Re: DexCom, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 14, 2022 Form 8-K Dated February 10, 2022 File No. 000-51222 Responses to Staff com |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DE |
|
| April 28, 2022 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended March 31, 2022 of the Company (the ?Report?) fully complies with the requirements of Section 13 |
|
| April 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 28, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| April 28, 2022 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| April 28, 2022 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended March 31, 2022 of the Company (the ?Report?) fully complies with the requirem |
|
| April 28, 2022 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| April 28, 2022 |
Exhibit 99.1 Dexcom Reports First Quarter 2022 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-April 28, 2022) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022. First Quarter 2022 Financial Highlights: ?Revenue grew 25% versus the same quarter of the prior year to $628.8 million on a reported basis and 22% on an organic1 basis. ?U.S |
|
| April 21, 2022 |
United States securities and exchange commission logo April 21, 2022 Kevin R. Sayer President and Chief Executive Officer DEXCOM, INC. 6340 Sequence Drive San Diego, California 92121 Re: DEXCOM, INC. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed on February 14, 2022 Form 8-K Dated February 10, 2022 Response Dated March 29, 2022 File No. 000-51222 Dear Mr. Sayer: We have reviewed your |
|
| April 8, 2022 |
DEF 14A 1 dxcm-2022xdef14aproxyapri.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use o |
|
| April 8, 2022 |
DEFA14A 1 defa14adxcm2022proxynotice.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| March 29, 2022 |
CORRESP 1 filename1.htm March 29, 2022 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Christie Wong Kristin Lochhead Re: DexCom, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 14, 2022 Form 8-K Dated February 10, 2022 File No. 000-51222 Responses to Staff |
|
| March 25, 2022 |
PRE 14A 1 dxcm-2022xpre14aproxyacti.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ☐ Check the appropriate box: ý Preliminary Proxy Statement ☐ Confidential, for Use o |
|
| March 22, 2022 |
United States securities and exchange commission logo March 22, 2022 Kevin R. Sayer President and Chief Executive Officer DEXCOM, INC. 6340 Sequence Drive San Diego, California 92121 Re: DEXCOM, INC. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed on February 14, 2022 Form 8-K Dated February 10, 2022 File No. 000-51222 Dear Mr. Sayer: We have limited our review of your filing to the fi |
|
| February 14, 2022 |
Exhibit 10.43 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE ("Amendment") is dated as of November 17, 2020 (the "Effective Date"), by and among GC PACIFIC CENTER COURT OWNER, LLC, a Delaware limited liability company ("Landlord"), and DEXCOM, INC., a Delaware corporation ("Tenant"). RECITALS A. Tenant and Landlord are parties to that certain lease dated as of January 31, 2020 (the "Lease" |
|
| February 14, 2022 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the annual Report on Form 10-K for the period ended December 31, 2021 of the Company (the “Report”) fully complies with the requirem |
|
| February 14, 2022 |
Consent of Independent Registered Public Accounting Firm Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: ◦Registration Statement (Form S-3 Nos. 333-206619, 333-211101, 333-228495, and 333-261265) of DexCom, Inc., ◦Registration Statement (Form S-8 No. 333-204699) pertaining to the 2015 Equity Incentive Plan and the 2015 Employee Stock Purchase Pl |
|
| February 14, 2022 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this annual report on Form 10-K of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51222 DEXCOM, INC. (Exact name of r |
|
| February 14, 2022 |
Tenant Estoppel Certificate - Sequence Exhibit 10.41 TENANT ESTOPPEL CERTIFICATE June 8, 2021 ARE-SD REGION NO. 76, LLC (?Buyer?) c/o Alexandria Real Estate Equities, Inc. 26 North Euclid Avenue Pasadena, California 91101 Re: Lease dated March 31, 2006 (together with all amendments, modifications, supplements, guarantees, and restatements thereof set forth in items 1 and 2 of Schedule A attached hereto, the ?Lease?) executed between Ki |
|
| February 14, 2022 |
Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated January 31, 2020 Exhibit 10.42 LEASE 10455 Pacific Center Court San Diego, California Basic Lease Information Date: January 31, 2020 Landlord: GC Pacific Center Court Owner LLC, a Delaware limited liability company Tenant: Dexcom, Inc., a Delaware corporation Building (section 1.1): That certain building located at 10455 Pacific Center Court, San Diego, California 92121 Premises (section 1.1): A portion of the Bui |
|
| February 14, 2022 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the “Company”), pursuant to 18 U.S.C. §1350, hereby certifies that: (i) the annual Report on Form 10-K for the period ended December 31, 2021 of the Company (the “Report”) fully complies with the requirements of Section 13 |
|
| February 14, 2022 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this annual report on Form 10-K of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| February 14, 2022 |
Exhibit 10.40 SIXTH AMENDMENT TO OFFICE LEASE This SIXTH AMENDMENT TO OFFICE LEASE ("Sixth Amendment") is made and entered into as of the 25th day of May, 2021, by and between SEQUENCE TECH. CENTER CA LLC, a Delaware limited liability company ("Landlord"), and DEXCOM, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord?s predecessor-in-interest, JOHN HANCOCK LIFE INSURANCE COMPA |
|
| February 14, 2022 |
Exhibit 10.39 SECOND AMENDED AND RESTATED CREDIT AGREEMENT dated as of October 13, 2021 by and among DEXCOM, INC., as Borrower, the Lenders party hereto, and JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, as Administrative Agent JPMORGAN CHASE BANK, NATIONAL ASSOCIATION, and MERRILL LYNCH, PIERCE, FENNER & SMITH INC., as Joint Bookrunners and Joint Lead Arrangers BANK OF AMERICA, N.A., and SILICON VAL |
|
| February 14, 2022 |
Exhibit 21.01 DEXCOM, INC. SUBSIDIARY (Name under which subsidiary does business) JURISDICTION OF INCORPORATION SweetSpot Diabetes Care, Inc. Delaware TypeZero Technologies, Inc. Delaware DexCapital, LLC Delaware The Glucose Program, LLC Delaware Nintamed Handels GmbH Austria DexCom Canada, Co. Canada DexCom (Canada) Inc. Canada DexCom Deutschland GmbH Germany DexCom Lithuania UAB Lithuania DexCom |
|
| February 14, 2022 |
Tenant Estoppel Certificate - Pacific Center Exhibit 10.44 TENANT ESTOPPEL CERTIFICATE The undersigned, Dexcom, Inc., a Delaware corporation ("Tenant"), hereby certifies to NR THE CANYONS LLC, a Delaware limited liability company, and its affiliates, successors and assigns ("Buyer") and any lenders and their successors and assigns that provide Buyer financing in connection with the Property (as defined below) as follows, with respect to that |
|
| February 14, 2022 |
Tenant’s Acceptance of Possession - Pacific Center Exhibit 10.45 Tenant?s Acceptance of Possession Premises Address: Expansion Premises per First Amendment dated November 10, 2020 10455 Pacific Center Court San Diego, CA 92126 Landlord: GC Pacific Center Court Owner, LLC Tenant: DexCom, Inc. As a representative of the above referenced tenant, I have physically inspected the suite noted above and its improvements with Dee Ordonez, Property Manager, |
|
| February 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 10, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) |
|
| February 10, 2022 |
Exhibit 99.1 Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-February 10, 2022) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights: ?Revenue grew 23% versus the same quarter of the prior year to $698.2 million on a reported |
|
| February 9, 2022 |
DXCM / DexCom, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Dexcom Inc. Title of Class of Securities: Common Stock CUSIP Number: 252131107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| January 10, 2022 |
Exhibit 99.01 Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial SAN DIEGO, CA - (BUSINESS WIRE-January 10, 2022) - DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (?CGM?), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2021 to be |
|
| January 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) |
|
| November 22, 2021 |
Exhibit 4.5 DEXCOM, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 ? DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 ? THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXECUTION AND AU |
|
| November 22, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 22, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File |
|
| November 22, 2021 |
S-3ASR 1 d260805ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 22, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DEXCOM, INC. (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdiction |
|
| November 22, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-261265 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered (1) Proposed maximum offering price per unit (2) Proposed maximum aggregate offering price (2) Amount of registration fee (3) Common Stock, $0.001 par value per share, issuable at the election of DexCom, Inc. upon |
|
| November 22, 2021 |
Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] DEXCOM, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY IS % |
|
| October 28, 2021 |
Exhibit 99.1 Dexcom Reports Third Quarter 2021 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-October 28, 2021) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights: ?Revenue grew 30% versus the same quarter of the prior year to $650.2 million on a reported basis and 28% on an organic1 basis |
|
| October 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 D |
|
| October 28, 2021 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| October 28, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| October 28, 2021 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies: (i) the quarterly Report on Form 10-Q for the period ended September 30, 2021 of the Company (the ?Report?) fully complies with the requireme |
|
| October 28, 2021 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended September 30, 2021 of the Company (the ?Report?) fully complies with the requirements of Sectio |
|
| October 28, 2021 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 13, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 9, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File |
|
| July 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 29, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| July 29, 2021 |
Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jereme M. Sylvain, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| July 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEXCOM |
|
| July 29, 2021 |
Exhibit 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies: (i) the quarterly Report on Form 10-Q for the period ended June 30, 2021 of the Company (the ?Report?) fully complies with the requirements o |
|
| July 29, 2021 |
Exhibit 99.01 Dexcom Reports Second Quarter 2021 Financial Results SAN DIEGO, CA - (BUSINESS WIRE-July 29, 2021) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2021. Second Quarter 2021 Financial Highlights: ?Revenue grew 32% versus the same quarter of the prior year to $595.1 million ?U.S. revenue growth of 26% and international revenue |
|
| July 29, 2021 |
Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). Exhibit 31.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kevin R. Sayer, certify that: 1. I have reviewed this quarterly report on Form 10-Q of DexCom, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| July 29, 2021 |
Exhibit 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C SECTION 1350 The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the ?Company?), pursuant to 18 U.S.C. ?1350, hereby certifies that: (i) the quarterly Report on Form 10-Q for the period ended June 30, 2021 of the Company (the ?Report?) fully complies with the requirements of Section 13(a |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Num |
|
| June 1, 2021 |
SD 1 a2021formsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT DEXCOM, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-51222 33-0857544 (State or other jurisdiction of incorporation or organization ) (Commission File Number) (IRS Employer Identification No.) 6340 Sequence Drive, San Diego, California 92 |
|
| June 1, 2021 |
DexCom, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2020. Exhibit 1.01 to Form SD DexCom, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2020 This Conflict Minerals Report (?CMR?) has been prepared by DexCom, Inc. (herein referred to, alternatively, as ?Dexcom,? ?we,? ?our? and ?us?). This CMR for the reporting period January 1 to December 31, 2020 is presented to comply with the final conflict minerals implementing rule |
|
| May 21, 2021 |
Exhibit 3.4 AMENDED & RESTATED BYLAWS OF DEXCOM, INC. (a Delaware corporation) As amended September 3, 2020 May 21, 2021 TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 Section 1.1. Annual Meetings 1 Section 1.2. Special Meetings 1 Section 1.3. Notice of Meetings 1 Section 1.4. Adjournments 1 Section 1.5. Quorum 1 Section 1.6. Organization 2 Section 1.7. Voting; Proxies 2 Section 1.8. Fixing Date |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2021 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51222 33-0857544 (Commission File Numb |
|
| May 21, 2021 |
Exhibit 3.2 DEXCOM, INC. RESTATED CERTIFICATE OF INCORPORATION DexCom, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the corporation is DexCom, Inc. The date of filing its original Certificate of Incorporation with the Secretary of State was May 13, 1999. This Restated Certificate of Incorporation of |
